Insulin receptor substrate 2 (IRS2) confers resistance to PI3K pathway inhibition in PIK3CA mutant breast cancer.

Lero MW, Morgan JS, Card MA, Zhu LJ, Li J, Li R, Bui QT, Mohlmann E, Goel HL, Shaw LM

Open source

DOI
10.1016/j.jbc.2026.113426
Published
2026 Aug 10
Container
The Journal of biological chemistry
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.jbc.2026.113426,
  title = {Insulin receptor substrate 2 (IRS2) confers resistance to PI3K pathway inhibition in PIK3CA mutant breast cancer.},
  author = {Lero MW and Morgan JS and Card MA and Zhu LJ and Li J and Li R and Bui QT and Mohlmann E and Goel HL and Shaw LM},
  year = {2026},
  journal = {The Journal of biological chemistry},
  doi = {10.1016/j.jbc.2026.113426},
  url = {https://doi.org/10.1016/j.jbc.2026.113426}
}

RIS

TY  - JOUR
TI  - Insulin receptor substrate 2 (IRS2) confers resistance to PI3K pathway inhibition in PIK3CA mutant breast cancer.
AU  - Lero MW
AU  - Morgan JS
AU  - Card MA
AU  - Zhu LJ
AU  - Li J
AU  - Li R
AU  - Bui QT
AU  - Mohlmann E
AU  - Goel HL
AU  - Shaw LM
PY  - 2026
JO  - The Journal of biological chemistry
DO  - 10.1016/j.jbc.2026.113426
UR  - https://doi.org/10.1016/j.jbc.2026.113426
ER  - 

APA

MW, L., JS, M., MA, C., LJ, Z., J, L., R, L., QT, B., E, M., HL, G., & LM, S. (2026). Insulin receptor substrate 2 (IRS2) confers resistance to PI3K pathway inhibition in PIK3CA mutant breast cancer.. The Journal of biological chemistry. https://doi.org/10.1016/j.jbc.2026.113426

Source records